Dutasteride CAS:164656-23-9

  • Product Name:Dutasteride
  • CAS:164656-23-9
  • Molecular formula:C27H30F6N2O2
  • Contact Supplier

Poroduct Description

Files Download:

COA:Downl oad MSDS:Downl oad

Dutasteride CAS:164656-23-9

Dutasteride CAS:164656-23-9 Basic information

Product Name: Dutasteride
Synonyms: Dutasteride API;(4aR,4bS,6aS,7S,9aS,9bS,11aR)-N-(2,5-Bis(trifluoroMethyl)phenyl)-4a,6a-diMethyl-2-oxo-2,4a,4b,5,6,6a,7,8,9,9a,9b,10,11,11a-tetradecahydro-1H-indeno[5,4-f]quinoline-7-carboxaMide;Dutasteride for system suitability;Dutasteride (200 mg);(5alp
CAS: 164656-23-9
MF: C27H30F6N2O2
MW: 528.53
EINECS: 638-758-5
Product Categories: Hormone Drugs;API;Miscellaneous Biochemicals;All Inhibitors;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Steroids;Steroid and Hormone
Mol File: 164656-23-9.mol

Dutasteride CAS:164656-23-9 Chemical Properties

density: 1.303±0.06 g/cm3(Predicted)
Melting point: 242-250°C
Boiling point: 620.3±55.0 °C(Predicted)
form: powder
storage temp.: -20°C Freezer
pka: 13.32±0.70(Predicted)
InChIKey: JWJOTENAMICLJG-QWBYCMEYSA-N
solubility: DMSO: soluble2mg/mL, clear
optical activity: [α]20/D +2.4°, c = 2 in ethanol

Items                                        

Specification

Results

Description                

White or off- white powder   

Off- white powder

Identification                                 

A:Infrared absorption.

complies

B:The retention time of the major peak of the sample solution corresponds to that of the standard solution,as obtained in the assay.

complies

Solubility  

Soluble in ethanol and methanol, slightly soluble in polyethylene glycol 400, and insoluble in water

 

complies

Residue on ignition                              

NMT 0.1%

0.04%

Heavy  Metals                                

Not more than 20ppm

complies

Water

NMT 0.50%

0.16%

Optical Rotation

+15.0° to +25.0° 

+20.4° 

Limit of platinum

NMT 5ug/g

complies

Limit of Residual Solvents

Acetonitrile NMT 0.3%

N.d

Ethyl acetate NMT 0.2%

0.0346%

Dioxane NMT 0.1%

N.d

n-Heptane NMT 0.5%

N.d

Pyridine NMT 0.2%

N.d

Toluene NMT 0.2%

0.024%

Organic Impurities

Procedure 1

Dutasteride acid NMT 0.2%

N.d

Dutasteride dimethylamide NMT0.2%

0.03%

Dutasteride methyl ester NMT 0.15%

0.04%

Dutasteride ethyl ester NMT 0.2%

N.d

Dutasteride 17α-5-ene NMT 0.2%

N.d

Dutasteride 17α-epimer NMT 0.3%

N.d

Chlorodutasteride NMT 0.4%

0.27%

Dutasteride -5-ene NMT 0.3%

N.d

Any other individual impurity NMT 0.1%

0.04%

Organic Impurities

Procedure 2

Dihydrodutasteride NMT 0.15%

N.d

Dutasteride α-dimer NMT 0.3%

N.d

Dutasteride β-dimer NMT 0.5%

N.d

Any other individual impurity NMT 0.1%

0.05%

Total impurities NMT 2.0%

0.31%

Dutasteride Usage And Synthesis
Indications and UsageDutasteride is the first and only double 5α reductase inhibitor used to treat prostatic hyperplasia, and it is mainly used clinically to treat prostate enlargement, male-pattern hair loss, seborrheic hair loss, and hereditary hair loss.
Mechanisms of ActionThe human body contains type I and type II 5α reductase, with type II found mainly in the prostate, and type I found mainly in the liver and skin. 5α reductase is the main cause for continuous benign prostate enlargement; it promotes the transformation of testosterone in patients’ prostate into the more active dihydrotestosterone, thus causing prostate cells to enlarge and the prostate to swell. Dutasteride can inhibit both type I and II 5α reductase at the same time. This type of simultaneous inhibiting mechanism can rapidly and continuously reduce prostate size, dramatically improve urination, and reduce the risk fo acute urinary retention and its related prostate surgeries.
Clinical ResearchThe American FDA approved a 2-year multicenter randomized double-blind control clinical trial – the first long term clinical assessment of the combined usage of Dutasteride and α receptor blockers. Included subjects were male patients with moderate to severe prostate enlargement (ages greater than or equal to 50, prostate volume (PV) ≥30 cc, serum prostate specific antigen (PSA) levels 1.5-10ng/ml, 5ml/sec < maximum urinary flow (Qmax) ≤15ml/sec, minimum urination ≥ 125ml, international prostate symptom score (IPSS) ≥ 12). Patients were first given a placebo for 4 weeks and then were randomly given either 0.5mg/day of Dutasteride and 0.4mg/day of Tamsulosin, only 0.5mg/day of Dutasteride, or only 0.4mg/day of Tamsulosin.
Results showed: After 12-24 months, the combined usage of Dutasteride with Tamsulosin had better curative effects than did individual usage.
Side EffectsErectile dysfunction, reduced libido, breast diseases (including enlarged or swelling breasts), ejaculation difficulties and dizziness.
ContradictionsNot to be used by women and children.
DescriptionDutasteride was launched for the symptomatic treatment of benign prostatic hyperplasia. Dutasteride can be prepared from 3-oxo-4-androstene-17β-carboxylic acid by several ways in 6 or 8 steps. Dutasteride is a dual inhibitor of type 1 and 2 isoforms of 5α-reductase unlike finasteride, the first marketed 5α-reductase inhibitor, which only acts on type 2 isozyme. Dutasteride is a 3-fold greater inhibitor of type-2 5α-reductase than finasteride in men and has greater effect on the type-l than on type-2 isozyme. In animal models,dutasteride exhibited superior efficacy and pharmacokinetics compared to finasteride. In patients with benign prostate hyperplasia, administration of dutasteride was shown to dose-dependently decrease serum dihydrotestosterone levels with greater efficacy as compared to finasteride (95% vs 67%). Serum testosterone levels increased with both active drugs, in conjunction with dihydrotestosterone suppression but remained within normal ranges. In long term studies, in men with moderate to severe benign prostate hyperplasia, once daily dutasteride significantly reduced prostate volume, reduced the risk of acute urinary retention and surgery by 57% and improved lower urinary tract symptoms and urinary flow measurements. After oral administration, dutasteride is rapidly absorbed, has a short distribution phase and a mean bioavailability of 60%. The high volume of distribution, combined with its low linear clearance results in a prolonged dose dependent half-life (from 3 days at low concentrations to 5 weeks at high concentrations) whereas finasteride’s half-life time is approximately 10 h. Dutasteride is well tolerated and the most occurring adverse events are impotence, decrease in libido, ejaculation disorders and gynaecomastia. Unlike a-blockers which primarily act acutely on benign prostatic hyperplasia symptoms, 5a-reductase inhibitors can alter disease progression. Concomitant administration of dutasteride did not affect the pharmacokinetics of either tamsulosin or terazosin. In addition, the tolerability of both terazosin and tamsulosin were improved during combination therapy.
Chemical PropertiesWhite Crystalline Solid
OriginatorGlaxoSmithKline (UK)
UsesUsed in the treatment of benign prostatic hyperplasia. Dual inhibitor of 5a-reductase isoenzymes type 1 and 2; structurally related to Finasteride.
UsesUsed in the treatment of benign prostatic hyperplasia. Dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to Finasteride.
Usesantihypertensive, ACE inhiibitor
UsesDutasteride is a dual inhibitor of 5α-reductase isoenzymes type 1 and 2; structurally related to Finasteride (F342000). Dutasteride is used in the treatment of benign prostatic hyperplasia.
DefinitionChEBI: Finasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.
Brand nameAvodart (GlaxoSmithKline).
Biological FunctionsSimilar to finasteride, dutasteride is a competitive and mechanism-based inhibitor not only of type 2 but also of type 1 5α-reductase isoenzymes, with which stable enzyme-NADP adduct complexes are formed, inhibiting the conversion of testosterone to DHT. The suppression of both type 1 and type 2 isoforms results in greater and more consistent reduction of plasma DHT than that observed for finasteride. The more effective dual inhibition of type 1 and type 2 5α-reductase isoforms lowers circulating DHT to a greater extent than with finasteride and shows advantages in treating BPH and other disease states (e.g., prostate cancer) that are DHT-dependent.
PharmacokineticsThe maximum effect of 0.5 mg daily doses of dutasteride on the suppression of DHT is dose-dependent and is observed within 1 to 2 weeks. After 2 weeks of 0.5 mg daily dosing, median plasma DHT concentrations were reduced by 90%, and after 1 year, the median decrease in plasma DHT was 94%. The median increase in plasma testosterone was 19% but remained within the physiological range. The drug also reduced serum prostatic specific antigen by approximately 50% at 6 months and total prostate volume by 25% at 2 years. Dutasteride produced improvements in quality of life and peak urinary flow rate and reduction of acute urinary retention without the need for surgery.
Side effectsThe main side effects are ED, decreased libido, gynecomastia, and ejaculation disorders. Long-term use (>4 years), however, did not reveal increased onset of sexual side effects. In addition, the combination of dutasteride and tamsulosin is well-tolerated and has the added advantage of rapid symptomatic relief.


You need any help?

Related Content

Ursodeoxycholic acid CAS:128-13-2

Ursodeoxycholic acid CAS:128-1…

Prostaglandin E1 Impurity 2 CAS:745-65-3

Prostaglandin E1 Impurity 2 CA…

Arbutin CAS:497-76-7

Arbutin CAS:497-76-7

Sucrose CAS:57-50-1

Sucrose CAS:57-50-1

L(+)-Diethyl L-tartrate CAS:87-91-2

L(+)-Diethyl L-tartrate CAS:87…

2-Nitrophenyl-beta-D-galactopyranoside CAS:369-07-3

2-Nitrophenyl-beta-D-galactopy…

Hesperidin methylchalcone CAS:24292-52-2

Hesperidin methylchalcone CAS:…

D-Glucosamine hydrochloride CAS:66-84-2

D-Glucosamine hydrochloride CA…

L-FUCOSE CAS:2438-80-4

L-FUCOSE CAS:2438-80-4

Methyl L-tyrosinate hydrochloride CAS:3417-91-2

Methyl L-tyrosinate hydrochlor…

Artemisinin CAS:63968-64-9

Artemisinin CAS:63968-64-9

Hesperidin CAS:520-26-3

Hesperidin CAS:520-26-3

Vildagliptin CAS:274901-16-5

Vildagliptin CAS:274901-16-5

L-Cysteine CAS:52-90-4

L-Cysteine CAS:52-90-4

Vitamin D2 CAS:50-14-6

Vitamin D2 CAS:50-14-6

Address:303 FUTURE CITY,LIXIA DISTRICT,JINAN CITY,SHANDONG PROVINCE,CHINA Post Encoding:250000 Email:sales@bosschemical.com
Tel:8613280017993 Mobile:8613280017993 Fax:86-531-68657995

Link